Published online Dec 24, 2021. doi: 10.5306/wjco.v12.i12.1227
Peer-review started: January 19, 2021
First decision: May 14, 2021
Revised: May 25, 2021
Accepted: November 25, 2021
Article in press: November 25, 2021
Published online: December 24, 2021
Processing time: 339 Days and 6.9 Hours
Ameloblastic fibromas and ameloblastic fibrosarcomas are rare odontogenic tumors, and controversy exists in the classification of cases presenting hard-tissue production: Ameloblastic fibrodentinoma (AFD) and ameloblastic fibro-odontoma (AFO). These cases are currently considered “developing odontomas” (hamartomatous lesions). There is still controversy as to whether they are true hamartomas or neoplasms.
The authors consider that the recent 2017 WHO classification does not clarify the subject when considering AFD and AFO as “developing odontomas”. According to the clinical, radiographical, histopathological and molecular features of the cases reviewed, we suggest that AFD and AFO should continue to be considered benign neoplasms.
The objective was to analyze the clinicopathologic features of these lesions and discuss the changes in the 2017 WHO classification.
For this systematic review an electronic literature search was performed in the PubMed/MEDLINE database. An exhaustive search was made of all the existing information on these mixed odontogenic tumors.
Several aspects of AFO and AFD, such as biological behavior, age of occurrence, amount of hard tissue, and potential for malignant transformation into odontogenic sarcomas, support the neoplastic nature in most of the reported cases.
Considering the clinical, radiographic, histopathological, and molecular characteristics of odontogenic lesions with hard tissue production, we suggest that these types of lesions should continue to be recognized as odontogenic tumors by maintaining the classically used terms. This recommendation will be relevant for future clinical, microscopic, and molecular studies to better understand the biology of these interesting odontogenic tumors. This new information will be relevant for the clinical conduct to be followed in these tumors.
Future research should be focused on the comparative molecular study between these odontogenic neoplasms and odontomas; trying to clarify molecular differences between neoplasia and hamartoma.